Ocular Therapeutix (OCUL) Earnings Date & Reports

Key Takeaways

• Ocular Therapeutix is scheduled to report third-quarter 2026 results for the period ended September 30, 2026, before the market opens on Monday, November 9, 2026.
• Wall Street consensus points to a net loss of roughly $0.36 per share on revenue of approximately $14 million, versus a loss of $0.38 per share and $14.54 million in revenue in the prior-year quarter.
• Investor attention is likely to center on the regulatory timeline for AXPAXLI, the company's lead candidate for wet age-related macular degeneration (wet AMD, a progressive eye disease that can cause vision loss), rather than on near-term financials.
• In its most recent quarter, the company posted a loss of $0.35 per share and revenue of $13.48 million, beating analyst expectations on both measures.
• The company reported roughly $598.6 million in cash and equivalents as of June 30, 2026, providing a runway it has described as extending into 2028.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for OCUL.
• You can also discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on therapies for diseases of the eye, built around its proprietary hydrogel-based drug delivery platform. While the company still generates modest revenue, the market increasingly values it on the progress of AXPAXLI, its investigational sustained-release treatment for wet AMD. The upcoming report arrives at a pivotal moment, with management targeting a New Drug Application (NDA, the formal request for U.S. marketing approval) submission in the fourth quarter of 2026 following positive Phase 3 SOL-1 trial results. Because the shares trade primarily on clinical and regulatory milestones rather than quarterly profit, investors will be listening closely for updates on the submission timeline, spending trends, and cash runway.

Earnings Expectations

For the third quarter ended September 30, 2026, analysts expect Ocular Therapeutix to report a net loss of approximately $0.36 per share (EPS, or earnings per share), according to consensus estimates, with revenue projected near $14 million. That compares with a loss of $0.38 per share and revenue of $14.54 million in the same period a year earlier. In the prior quarter, the company posted a loss of $0.35 per share on revenue of $13.48 million, beating consensus estimates of a $0.40 loss and $13.20 million in revenue. Investors will also watch research and development (R&D) spending, which has climbed as the company advances AXPAXLI toward a regulatory filing, and commentary on its cash position, which stood at approximately $598.6 million at the end of the second quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like OCUL ahead of catalysts, it offers a structured way to surface relevant setups and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around OCUL is closely tied to the AXPAXLI regulatory story. The stock has experienced notable volatility in recent months as investors weigh the drug's clinical data against a competitive wet AMD landscape that includes established anti-VEGF (vascular endothelial growth factor) therapies. Key risk factors ahead of the print include any change to the NDA submission timeline, unexpected cost escalation in R&D, or softer-than-expected commercial revenue. Because the company remains pre-approval for AXPAXLI, the market may react more sharply to regulatory and clinical commentary than to the headline loss figures.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, the most important disclosures in this report will be qualitative. Management's commentary on the AXPAXLI NDA submission—still expected in the fourth quarter of 2026—remains the central catalyst. Investors should watch for confirmation that the submission remains on schedule and for any updates from recent interactions with the U.S. Food and Drug Administration (FDA).

Cost trends will also matter. R&D expenses have risen significantly as the company advances its clinical programs, and investors will want evidence that spending is tracking in line with the stated runway into 2028. Any meaningful upward revision in projected burn could weigh on sentiment.

Finally, the competitive backdrop deserves attention. Wet AMD is a crowded therapeutic area, and how management frames AXPAXLI's differentiation—particularly its sustained-release profile—could shape the market's interpretation of its commercial potential. Guidance updates, cash balance, and trial-enrollment progress are likely to round out the key items to monitor following the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations